The frequency of missed breast cancers in women participating in a high-risk MRI screening program

AbstractPurposeTo evaluate the frequency of missed cancers on breast MRI in women participating in a high-risk screening program.MethodsPatient files from women who participated in an increased risk mammography and MRI screening program (2003 –2014) were coupled to the Dutch National Cancer Registry. For each cancer detected, we determined whether an MRI scan was available (0–24 months before cancer detection), which was reported to be negative. These negative MRI scans were in consensus re-evaluated by two dedicated breast radiolog ists, with knowledge of the cancer location. Cancers were scored as invisible, minimal sign, or visible. Additionally, BI-RADS scores, background parenchymal enhancement, and image quality (IQ; perfect, sufficient, bad) were determined. Results were stratified by detection mode (mammography, MRI, in terval cancers, or cancers in prophylactic mastectomies) and patient characteristics (presence ofBRCA mutation, age, menopausal state).ResultsNegative prior MRI scans were available for 131 breast cancers. Overall 31% of cancers were visible at the initially negative MRI scan and 34% of cancers showed a minimal sign. The presence of aBRCA mutation strongly reduced the likelihood of visible findings in the last negative MRI (19 vs. 46%,P 
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research

Related Links:

Title: Hormone Therapy in Survivors of Breast CancerCategory: Doctor's&Expert's views on SymptomsCreated: 5/31/2001 12:00:00 AMLast Editorial Review: 6/13/2018 2:55:07 PM
Source: MedicineNet Menopause General - Category: Primary Care Source Type: news
Conclusions: The presence of the G/G genotype of XbaI may be considered a susceptibility allele in Mexican women. Due to increased postmenopausal BC risk, the XbaI (WT/G or G/G) alleles may be used as a postmenopausal predictive factor for BC in Mexican women.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: Based on our results, we concluded that modified Bloom–Richardson (MBR) grading has been recognized as a treatment related indicator. The accuracy and reliability in grading have always been a matter of concern, hence, the reproducibility of grading should be enhanced. Ki-67-a proliferation marker is easily identified and provides comparable accurate information. In contrast to poor reproducibility of mitotic counts, Ki-67 can achieve high agreement between pathologists; is more reproducible; adds complementary value to the MBR grading system and correlates well with other clinicopathologic parameters. It...
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: Palbociclib has clinical activity as a single agent in women with moderately pre-treated, oestrogen receptor-positive, HER2-negative advanced breast cancer. Palbociclib may have potential to reverse endocrine resistance in patients with a history of previous durable response to ET. Clinical trial information: NCT02549430. PMID: 29893790 [PubMed - as supplied by publisher]
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Oncol Source Type: research
ConclusionBreast density is an independent and significant risk factor for development of contralateral breast cancer. This risk factor should contribute to clinical decision making.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsOur results do not support associations between T2DM and/or GDM and higher amount of mammographically dense breast tissue, suggesting that the mechanism linking diabetes with breast cancer risk may not include mammographic breast density  in midlife.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
Phyllis Lacetti found her own breast cancer when she felt an abnormal lump in her right breast in 2007. A nurse at Montefiore Medical Center, she had a lumpectomy to remove it, but an MRI afterward revealed remaining cancer cells, so she opted to get a mastectomy. Her cancer doctor recommended she get chemotherapy to ensure that her cancer wouldn’t recur, since Lacetti’s family history put her at high risk. Her sister and father had died of leukemia, and her brother passed away from thyroid cancer. Chemotherapy, he said, was her best option for preventing the cancer from returning. But Lacetti was reticent abo...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer healthytime Source Type: news
This study aims to assess the patterns of development of on-treatment cardiac side effects among patients with early breast cancer receiving anthracycline-based chemotherapy. METHODS: This is a pooled analysis of patient-level data of patients with early-stage breast cancer who were recruited into three clinical trials to receive different adjuvant chemotherapy regimens. Univariable and multivariable analyses of factors predicting the development of on-treatment cardiac adverse events were conducted through logistic regression analysis. The following factors were evaluated in the univariable analysis: age, menopausal ...
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
Breast cancer (BC) is one of the most common invasive cancers in women worldwide, comprising 22.9% of invasive cancers, and is the second main cause of cancer death in women [1]. Based on clinical studies, synthetic progestogens (also called progestins) may play a crucial role in the development of BC with the use of contraception and hormone therapy in reproductive and menopausal women [2]. Norethisterone (NET), a progestin, is a medication used in combination with estrogen or alone in hormone therapy.
Source: Maturitas - Category: Primary Care Authors: Source Type: research
Abstract Breast cancer is the main risk associated with menopause hormone therapy (MHT). It is a hormone-dependent cancer. In postmenopausal women, about 80% of cases are estradiol receptor-positive. In cohort studies only estradiol receptor-positive breast cancers are promoted by MHT. Different levels of risk with estrogen-only treatment and combined treatment with estrogen + progestin are shown in randomized trials and observational studies. Several non-randomized studies show a lower risk with progesterone and retroprogesterone than with synthetic progestins. Progesterone and progestin are non-sel...
Source: Climacteric - Category: Geriatrics Authors: Tags: Climacteric Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Mammography | Mastectomy | Men | Menopause | Netherlands Health | PET Scan | Study | Women